These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28951612)

  • 21. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies.
    Verstrepen BE; Depla E; Rollier CS; Mares G; Drexhage JA; Priem S; Verschoor EJ; Koopman G; Granier C; Dreux M; Cosset FL; Maertens G; Heeney JL
    J Infect Dis; 2011 Sep; 204(6):837-44. PubMed ID: 21849281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining Breadth of Hepatitis C Virus Neutralization.
    Kinchen VJ; Bailey JR
    Front Immunol; 2018; 9():1703. PubMed ID: 30116237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
    Swadling L; Capone S; Antrobus RD; Brown A; Richardson R; Newell EW; Halliday J; Kelly C; Bowen D; Fergusson J; Kurioka A; Ammendola V; Del Sorbo M; Grazioli F; Esposito ML; Siani L; Traboni C; Hill A; Colloca S; Davis M; Nicosia A; Cortese R; Folgori A; Klenerman P; Barnes E
    Sci Transl Med; 2014 Nov; 6(261):261ra153. PubMed ID: 25378645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.
    Kumar A; Das S; Mullick R; Lahiri P; Tatineni R; Goswami D; Bhat P; Torresi J; Gowans EJ; Karande AA; Das S
    Vaccine; 2016 Feb; 34(8):1115-25. PubMed ID: 26700891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.
    Alvarez-Lajonchere L; Dueñas-Carrera S
    Int Rev Immunol; 2012 Jun; 31(3):223-42. PubMed ID: 22587022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.
    Meunier JC; Gottwein JM; Houghton M; Russell RS; Emerson SU; Bukh J; Purcell RH
    J Infect Dis; 2011 Oct; 204(8):1186-90. PubMed ID: 21917891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development.
    Bukh J; Forns X; Emerson SU; Purcell RH
    Intervirology; 2001; 44(2-3):132-42. PubMed ID: 11509874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B-cell characteristics define HCV reinfection outcome.
    Underwood AP; Gupta M; Wu BR; Eltahla AA; Boo I; Wang JJ; Agapiou D; Abayasingam A; Reynaldi A; Keoshkerian E; Zhao Y; Brasher N; Walker MR; Bukh J; Maher L; Gordon T; Davenport MP; Luciani F; Drummer HE; Lloyd AR; Bull RA
    J Hepatol; 2024 Sep; 81(3):415-428. PubMed ID: 38604387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies.
    Beaumont E; Joël Clément B; Guérin V; Chopin L; Roch E; Gomez-Escobar E; Roingeard P
    Liver Int; 2020 Aug; 40(8):1865-1871. PubMed ID: 32458507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.
    Lange M; Fiedler M; Bankwitz D; Osburn W; Viazov S; Brovko O; Zekri AR; Khudyakov Y; Nassal M; Pumpens P; Pietschmann T; Timm J; Roggendorf M; Walker A
    PLoS One; 2014; 9(7):e102235. PubMed ID: 25014219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation.
    Martinez-Donato G; Amador-Cañizares Y; Alvarez-Lajonchere L; Guerra I; Pérez A; Dubuisson J; Wychowsk C; Musacchio A; Aguilar D; Dueñas-Carrera S
    Vaccine; 2014 Mar; 32(15):1720-6. PubMed ID: 24486345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.
    Phelps CC; Walker CM; Honegger JR
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Wang X; Yan Y; Gan T; Yang X; Li D; Zhou D; Sun Q; Huang Z; Zhong J
    Gut; 2019 Jan; 68(1):140-149. PubMed ID: 29180585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.
    Schlotthauer F; McGregor J; Drummer HE
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33946211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody Responses in Hepatitis C Infection.
    Law M
    Cold Spring Harb Perspect Med; 2021 Mar; 11(3):. PubMed ID: 32341067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
    Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
    Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery.
    Christiansen D; Earnest-Silveira L; Grubor-Bauk B; Wijesundara DK; Boo I; Ramsland PA; Vincan E; Drummer HE; Gowans EJ; Torresi J
    Sci Rep; 2019 Jun; 9(1):9251. PubMed ID: 31239471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
    Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
    Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.